Business
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and
About this update from Vivos Therapeutics, Inc.
[{"type":"text","content":"LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA)), today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Vivos common stock for gross proceeds to the Company of approximately $4.0 million. As part of this transaction, the investor agreed to exercise the existing warrant (which was originally issued in November 2023 and had an exercise price of $3.83 per share) at a revised exercise price of $4.02 per share. The resale of the shares of common stock issuable upon exercise of the warrant were registered pursuant to an effective registration statement on Form S-1 (No. 333-275726). In consideration for the immediate exercise of the existing warrant for cash, Vivos has agreed to issue to the investor two new unregistered warrants, each to purchase 735,296 shares of common stock (or an aggregate of 1,470,592 shares) at an exercise price of $5.05 per share. The new warrants will be exercisable immediately upon issuance. Such warrants are identical, except that one warrant has a term of five years and the second warrant has a term of eighteen months. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering. The transaction is expected to close no later than February 20, 2024, subject to satisfaction of customary closing conditions. Vivos intends to use the net proceeds from the exercise for general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the \"Securities Act\"), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from th...